ADVERTISEMENT

Complete Response Letters

Atara In Disarray As Shares Sink On Ebvallo CRL

The Pierre Fabre-partnered allogeneic T-cell immunotherapy is already available in Europe but hopes of a US approval have been hit by a complete response letter citing problems at a third-party manufacturing facility.

Exit Interview: US FDA’s Patrizia Cavazzoni Says CDER Staff In ‘Best Place Possible’

During a virtual appearance at a CERSI meeting two days after announcing retirement plans, the CDER director also said she wished agency reviews of unapproved drugs could be published.

Tanvex Takes A Hit On Trastuzumab With CRL In US

Tanvex has seen its application for a trastuzumab biosimilar knocked back by the US Food and Drug Administration, receiving a complete response letter over the filing.

PharmaTher’s Ketamine Formulation Receives CRL From FDA

After sharing multiple updates to the regulatory status of its ketamine formulation, PharmaTher received a complete response letter from the FDA, which required minor information and clarifications from the company.

Vanda’s Tradipitant Gets CRL In Gastroparesis But Another NDA Filing Is Still On

The company will file a new drug application with the US FDA by the end of the year for tradipitant in a different indication, motion sickness.

Vanda’s Tradipitant Gets CRL In Gastroparesis But Another NDA Filing Is Still On

The company will file a new drug application with the US FDA by the end of the year for tradipitant in a different indication, motion sickness.

Stock Watch: Do Regeneron And BridgeBio Stock Movements Signal Smarter Investors?

Historically, announcements from biotech companies have triggered stock price fluctuations as investors misinterpret the details. However, two recent instances suggest this pattern might be shifting.

US FDA Advisory Committee Conduct Could Take Center Stage in Lykos Appeal of MDMA Rejection

Sponsor of psychedelic PTSD treatment will try rarely successful formal dispute resolution process after receiving a complete response letter. 

Steady On For US FDA’s Novel Approvals At Mid-Year, But Another 2023 Is Unlikely

US FDA would need to approve 44 novel agents by year-end to match 2023’s big total, but only 40 candidates are known to have user fee goals in the second half of 2024.

Novo Nordisk’s Weekly Insulin Trips Just Before Finish Line

The drug maker said the US FDA issued a complete response letter for insulin icodec that included requests related to manufacturing process and the type 1 diabetes indication.